Laxmi India Finance Q1: PAT jumps 70% YoY to ₹16.6 Cr, revenue up 34%; margin eases QoQ
PAT +69.54% YoY · revenue +34.18% · margins compressing
₹93.5 Cr
+34.18% YoY
₹16.57 Cr
+69.54% YoY
17.64%
+3.7pp YoY
₹3.17
Laxmi India Finance's standalone Q1 FY27 print is a clean YoY beat: total income rose 34.0% to ₹93.92 Cr and PAT rose 69.5% to ₹16.57 Cr against the year-ago quarter, with no exceptional items on either side so the reported growth is also the underlying growth. That YoY PAT pace runs well ahead of the 40-45% full-year PAT growth management guided at the Q4 FY26 concall (bullish tone, 'very optimistic' outlook) — an early on-track-to-beat signal for that target, though a single quarter running hot doesn't guarantee the full-year average holds. No formal Q1-specific street consensus could be located; the only analyst commentary found points to a much lower ~15-20% PAT growth expectation for FY27 overall, so this print, if representative, would be running materially ahead of that broader market expectation too — treat as directional, not a confirmed beat, since no quarter-specific estimate exists.
Q1 FY-2027 vs prior quarters
Sequentially the picture is softer: revenue was flat QoQ (+0.7%) while PAT fell 19.2% versus Q4 FY26's ₹20.52 Cr, and net profit margin eased to roughly 17.5% (company's own ratio: 17.49%) from 21.95% in Q4 FY26 — though it remains well above the 13.95% NPM a year ago. The compression traces to the expense side: total expenses rose 8.5% QoQ to ₹72.01 Cr, led by a 45% jump in impairment/credit-cost provisioning (₹3.69 Cr vs ₹2.55 Cr) and a 16.7% rise in employee benefits expense (₹22.12 Cr vs ₹18.94 Cr) — the latter consistent with Q1 typically carrying annual increments and fresh ESOP grants (the company issued options under its 2023 ESOP scheme this quarter and allotted 1,25,203 shares against prior exercises). Finance costs also rose 5.9% QoQ to ₹38.38 Cr even as management had guided a further 20-25 bps cut in cost of borrowing — a line worth tracking next quarter since a rising cost of funds would work against the margin-expansion thesis in the guidance. No management press release was available in the context to cross-check the company's own framing of the quarter. Balance-sheet metrics stayed comfortable: net worth ₹482.12 Cr, CRAR 25.32%, debt-equity 3.10x, and asset quality contained (Gross Stage-3 2.08%, Net Stage-3 0.94%).
For context: this is the second-highest quarterly PAT of the last 4 quarters; PAT has now risen for 2 consecutive quarters; revenue is at a 4-quarter high.
What the summary numbers don't show
Basic EPS ₹3.17 vs ₹4.06 in Q4 FY26 and ₹2.34 a year ago
Management guides for medium-term AUM to compound at 30-35% annually, with PAT growth targeted at an accelerated 40-45% for the current fiscal year. This growth is expected to be driven by calibrated geographical expansion into new states and improving productivity in maturing branches, while maintaining focus on the s
— This quarter: beat
W1
Whether the QoQ NPM compression (21.95% → ~17.5%) is one-quarter increment/ESOP seasonality or a durable trend — check Q2 FY27 employee cost run-rate
W2
Cost of borrowing trajectory: finance costs rose 5.9% QoQ to ₹38.38 Cr despite management's guided 20-25 bps reduction — confirm whether the cut shows up next quarter
W3
Credit cost trend: impairment provisioning jumped 45% QoQ to ₹3.69 Cr — watch Gross Stage-3 (currently 2.08%) for further movement
Filing is standalone-only (no consolidated statement, single-entity NBFC); figures in ₹ Lakhs in source, converted to Cr. No exceptional items in current or comparison periods. EPS shown as 'Basic 3.17' per Reg 52(4) annexure (a P&L table OCR artefact reads it as 3.07, but 3.17 is confirmed independently in the ratio disclosure and is arithmetically consistent with PAT/shares). Total Comprehensive Income (₹16.43 Cr) used by the company for its own NPM/net-worth ratio calc differs slightly from standalone PAT (₹16.57 Cr) due to OCI (remeasurement loss on defined benefit plans).
Informational and educational content only. Not investment advice.